<DOC>
	<DOCNO>NCT00079352</DOCNO>
	<brief_summary>This phase I trial study side effect best dose flavopiridol give together gemcitabine irinotecan treating patient unresectable metastatic solid tumor . Drugs use chemotherapy , flavopiridol , gemcitabine , irinotecan , work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell</brief_summary>
	<brief_title>Flavopiridol , Gemcitabine , Irinotecan Treating Patients With Unresectable Metastatic Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose recommended phase II dose flavopiridol combination gemcitabine irinotecan patient unresectable metastatic solid tumor . II . Determine toxicity profile regimen patient . OUTLINE : This dose-escalation study flavopiridol . Patients receive gemcitabine IV 30 minute follow irinotecan IV 30 minute day 1 15 . Patients also receive flavopiridol IV 60 minute day 2 16 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos flavopiridol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>Histologically confirm solid tumor metastatic unresectable Standard curative palliative measure exist longer effective No known brain metastasis Performance status ECOG 02 Performance status Karnofsky 60100 % More 12 week WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin normal AST ALT ≤ 2.5 time upper limit normal Creatinine normal Creatinine clearance ≥ 60 mL/min No venous thrombosis within past 6 month No thrombotic cerebrovascular accident within past 6 month No myocardial infarction within past 6 month No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No ongoing active infection No prior allergic reaction attribute compound similar chemical biological composition study agents No concurrent uncontrolled medical condition would preclude study participation No psychiatric illness social situation would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Prior biologic therapy allow More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Prior endocrine therapy allow More 4 week since prior radiotherapy recover Prior surgery allow No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>